VB 201

Drug Profile

VB 201

Alternative Names: CI-201; VB-201

Latest Information Update: 07 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator VBL Therapeutics
  • Class Anti-inflammatories; Phospholipids; Small molecules
  • Mechanism of Action CD14 antigen inhibitors; Cell movement inhibitors; Interleukin 12 subunit p40 inhibitors; Phospholipid modulators; Toll like receptor 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Atherosclerosis
  • Preclinical Hepatic fibrosis; Non-alcoholic fatty liver disease
  • No development reported Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis
  • Discontinued Plaque psoriasis; Ulcerative colitis

Most Recent Events

  • 03 Apr 2017 Pharmacodynamics data from a post-hoc analysis of phase II trials released by VBL Therapeutics
  • 09 Jan 2017 VB 201 is available for licensing as of 09 Jan 2017 http://www.vblrx.com/
  • 30 Jun 2015 VB 201 is still in phase II trials for Atherosclerosis in USA, Germany and Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top